Debt-to-equity improved to 0.50 with total debt at $8.2B, but goodwill of $25.6B (79% of assets) and a thin current ratio of 0.69 indicate impairment and liquidity risks.
| Total Current Assets | 4.27B | 4.54B | 5.72B | 4.82B | 4.06B | 5.25B | 5.01B | 5.81B |
| Cash & Short-Term Investments | 821.01M | 1.32B | 2.25B | 1.04B | 684M | 414M | 334M | 340M |
| Cash Only | 821.01M | 1.32B | 2.19B | 1.04B | 684M | 414M | 334M | 340M |
| Short-Term Investments | 0 | 0 | 55M | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 2.33B | 2.12B | 1.9B | 1.35B | 1.49B | 3.83B | 1.35B | 3.99B |
| Days Sales Outstanding | 34.98 | 70.13 | 61.87 | 43.66 | 49.99 | 146.27 | 49.74 | 171.91 |
| Inventory | 1.06B | 1.02B | 1.19B | 1.41B | 1.35B | 951M | 949M | 1.21B |
| Days Inventory Outstanding | 50.73 | 97.46 | 101.37 | 118.39 | 114.93 | 96.55 | 86.99 | 120.18 |
| Other Current Assets | 45.72M | 77.86M | 223M | 907M | 434M | 5M | 2.32B | 237M |
| Total Non-Current Assets | 28.12B | 28.03B | 28.6B | 29.24B | 30.76B | 29.2B | 29.12B | 29.9B |
| Property, Plant & Equipment | 2.05B | 1.99B | 1.92B | 1.9B | 1.9B | 1.66B | 1.6B | 1.62B |
| Fixed Asset Turnover | 11.33x | 5.53x | 5.85x | 5.94x | 5.72x | 5.74x | 6.17x | 5.23x |
| Goodwill | 0 | 8.13B | 8.2B | 8.32B | 8.4B | 8.25B | 8.27B | 8.17B |
| Intangible Assets | 25.59B | 17.49B | 18.01B | 18.54B | 20.04B | 18.95B | 18.95B | 19.84B |
| Long-Term Investments | 294.4M | 75.87M | 82M | 65M | 44M | 23M | 0 | 3M |
| Other Non-Current Assets | 123.25M | 104.82M | 383M | 415M | 157M | 8M | 51M | 10M |
| Total Assets | 32.38B | 32.57B | 34.31B | 34.05B | 34.81B | 34.45B | 34.13B | 35.71B |
| Asset Turnover | 0.68x | 0.34x | 0.33x | 0.33x | 0.31x | 0.28x | 0.29x | 0.24x |
| Asset Growth % | -7.26% | -5.08% | 0.76% | -2.18% | 1.06% | 0.94% | -4.43% | - |
| Total Current Liabilities | 6.21B | 4.92B | 5.81B | 4.64B | 4.37B | 4.24B | 4.01B | 4.27B |
| Accounts Payable | 3.77B | 3.72B | 1.97B | 1.85B | 1.83B | 1.58B | 1.83B | 1.9B |
| Days Payables Outstanding | 149.97 | 354.65 | 168.06 | 155.97 | 156.45 | 160.32 | 167.47 | 188.36 |
| Short-Term Debt | 1.95B | 834.53M | 1.44B | 608M | 393M | 874M | 348M | 481M |
| Deferred Revenue (Current) | 33.94M | 33.94M | 0 | 0 | 23M | 11M | 11M | 7M |
| Other Current Liabilities | 219.67M | 17.88M | 693M | 1.57B | 1.61B | 1.43B | 958M | 913M |
| Current Ratio | 0.69x | 0.92x | 0.98x | 1.04x | 0.93x | 1.24x | 1.25x | 1.36x |
| Quick Ratio | 0.52x | 0.71x | 0.78x | 0.73x | 0.62x | 1.01x | 1.01x | 1.08x |
| Cash Conversion Cycle | -64.27 | -187.06 | -4.83 | 6.08 | 8.46 | 82.51 | -30.74 | 103.73 |
| Total Non-Current Liabilities | 9.84B | 11.19B | 12.28B | 12.69B | 13.99B | 3.73B | 3.89B | 4.03B |
| Long-Term Debt | 6.14B | 7.66B | 8.54B | 8.71B | 9.89B | 1M | 0 | 0 |
| Capital Lease Obligations | 355.33M | 85M | 73M | 89M | 117M | 87M | 105M | 121M |
| Deferred Tax Liabilities | 13.04B | 3.22B | 3.35B | 3.49B | 3.6B | 3.36B | 0 | 3.51B |
| Other Non-Current Liabilities | 316.08M | 217.62M | 311M | 424M | 384M | 289M | 3.79B | 0 |
| Total Liabilities | 16.04B | 16.12B | 18.09B | 17.33B | 18.36B | 7.97B | 7.91B | 8.3B |
| Total Debt | 8.2B | 8.59B | 10.1B | 9.46B | 10.44B | 991M | 487M | 642M |
| Net Debt | 7.38B | 7.27B | 7.91B | 8.41B | 9.76B | 577M | 153M | 302M |
| Debt / Equity | 0.50x | 0.52x | 0.62x | 0.57x | 0.63x | 0.04x | 0.02x | 0.02x |
| Debt / EBITDA | 1.50x | 3.11x | 4.21x | 4.10x | 4.94x | 0.52x | 0.26x | 0.55x |
| Net Debt / EBITDA | 1.35x | 2.63x | 3.29x | 3.65x | 4.62x | 0.30x | 0.08x | 0.26x |
| Interest Coverage | 7.70x | 7.60x | 5.88x | 4.93x | 5.46x | 121.44x | 62.62x | 32.49x |
| Total Equity | 16.34B | 16.46B | 16.22B | 16.73B | 16.46B | 26.48B | 26.22B | 27.41B |
| Equity Growth % | -3.7% | 1.42% | -3.02% | 1.65% | -37.85% | 0.98% | -4.34% | - |
| Book Value per Share | 3.66 | 3.65 | 3.54 | 3.61 | 3.56 | 5.73 | 5.68 | 5.94 |
| Total Shareholders' Equity | 16.28B | 16.4B | 16.17B | 16.61B | 16.33B | 26.36B | 26.11B | 27.32B |
| Common Stock | 87.47M | 89.84M | 91M | 92M | 92M | 1M | 1M | 1M |
| Retained Earnings | 27.52B | 16.13B | 27.27B | 27.47B | 26.73B | 37.99B | 37.76B | 5.11B |
| Treasury Stock | 0 | -160.72M | -116M | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -11.33B | 335.41M | 761.46M | -10.96B | 1.2B | -11.63B | -11.65B | 1.37B |
| Minority Interest | 59.64M | 58.9M | 58M | 123M | 126M | 125M | 111M | 91M |
Regulatory and shareholder overhang
Haleon's total assets have contracted from $34.8B in 2022Q4 to $32.4B in 2026Q2, while debt-to-equity eased from 0.63 to 0.50, according to recent balance sheet data, indicating a deleveraging trend.
The reduction in total assets is primarily driven by a decline in goodwill from $28.5B in 2022Q2 to $25.6B in 2026Q2, reflecting divestitures and potential impairments. The balance sheet appears to be stabilizing as leverage metrics improve, but the asset base contraction suggests a portfolio reshaping that may limit future growth capacity. Investors should monitor whether this deleveraging is sustainable without sacrificing investment in core brands.
Total debt fell from $10.4B in 2022Q4 to $8.2B in 2026Q2, with D/E improving to 0.50, as per reported figures, but cash reserves remain thin at $821M, suggesting limited liquidity buffer.
The consistent reduction in absolute debt indicates a strategic focus on deleveraging, likely to regain investment-grade flexibility. However, the current ratio of 0.69 in 2026Q2 is below 1.0, implying potential short-term liquidity strain if cash flows weaken. The low cash balance relative to debt suggests that refinancing risk is manageable but warrants monitoring, especially given the seasonal nature of working capital.
Goodwill and intangibles constitute approximately 79% of total assets in 2026Q2, based on balance sheet data, while net PPE is only $2.0B, indicating an asset-light model with significant impairment risk.
The heavy reliance on goodwill from the demerger exposes the balance sheet to potential write-downs if brand performance falters. The modest PPE suggests low capital intensity, consistent with a consumer health model, but the concentration in intangibles means that any adverse regulatory or competitive developments could trigger impairments. The stability of PPE over time indicates limited reinvestment, which may be appropriate given the low capex requirements.
Equity remained stable around $16.3B in 2026Q2, while retained earnings surged to $27.5B from $26.7B in 2022Q4, as per balance sheet data, indicating strong profit retention despite dividend payments.
The increase in retained earnings suggests that Haleon is generating sufficient profits to support both dividends and reinvestment, even as it deleverages. However, the equity base is relatively flat, implying that share repurchases and dividends are offsetting earnings accretion. The stability of equity despite debt reduction indicates a balanced capital return policy, but investors should watch for potential dilution from stock-based compensation.
Current ratio dropped to 0.69 in 2026Q2 from 0.92 in 2025Q4, as reported in balance sheet data, with cash at $821M, suggesting a tight liquidity position that may strain during off-peak seasons.
The sub-1.0 current ratio indicates that current liabilities exceed current assets, which is unusual for a consumer staples company and may reflect aggressive working capital management or seasonal inventory build-up. The low cash balance relative to total debt of $8.2B suggests reliance on operating cash flow and credit facilities for short-term obligations. This warrants close monitoring, especially if revenue growth remains negative.
Goodwill of $25.6B in 2026Q2, as per balance sheet data, represents a significant portion of total assets, and any brand underperformance could trigger impairments that erode equity.
The large goodwill balance, inherited from the GSK demerger, is a non-cash asset that may not reflect the true economic value of the brands. If the company's growth stalls or regulatory actions (e.g., phenylephrine ruling) impact key products, impairment charges could be substantial, reducing reported equity and potentially affecting debt covenants. Investors should assess the recoverability of these intangibles based on segment cash flows and market conditions.
Quick answers to the most common questions about buying HLN stock.
As of 2025, Haleon plc (HLN) had total assets of $32.57B including $4.54B in current assets.
Haleon plc (HLN) carries total debt of $8.59B, offset by $1.32B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Haleon plc (HLN) has total shareholders' equity (book value) of $16.40B ($3.65 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Haleon plc (HLN) reported a current ratio of 0.92x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.